This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

BELLUS Health Valuation

Is BLU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BLU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BLU (CA$19.5) is trading above our estimate of fair value (CA$16.16)

Significantly Below Fair Value: BLU is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BLU?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for BLU. This is calculated by dividing BLU's market cap by their current preferred multiple.
What is BLU's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	n/a

BLU key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	103169.2x
Enterprise Value/EBITDA	-17.2x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does BLU's PB Ratio compare to its peers?

The above table shows the PB ratio for BLU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	7x
EPRX Eupraxia Pharmaceuticals	7.5x	n/a	CA$157.8m
SVA Sernova	n/a	69.1%	CA$84.6m
ONC Oncolytics Biotech	6.5x	41.4%	CA$125.6m
BCT BriaCell Therapeutics	n/a	-19.5%	CA$35.5m
BLU BELLUS Health	5.1x	46.1%	CA$2.5b

Price-To-Book vs Peers: BLU is good value based on its Price-To-Book Ratio (5.1x) compared to the peer average (32.2x).

Price to Earnings Ratio vs Industry

How does BLU's PE Ratio compare vs other companies in the CA Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	36.7%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	36.7%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: BLU is expensive based on its Price-To-Book Ratio (5.1x) compared to the Canadian Biotechs industry average (1.7x)

Price to Book Ratio vs Fair Ratio

What is BLU's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BLU PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	5.1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BLU's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.